AIM: To clarify whether serum chemokine and cytokine levels can become useful biological and functional markers to assess the severity of chronic pancreatitis (CP). This study aimed at clarifying whether serum chemokine and cytokine levels can become useful biological and functional markers to assess the severity of CP. METHODS: Serum monocyte chemoattractant protein-1 (MCP-1), transforming growth factor beta-1 (TGF-beta1), and soluble type fractalkine (s-fractalkine) concentrations were examined in patients with CP (n = 109) and healthy controls (n = 116). Severity of disease was classified in patients with CP by a staging system. Relationships between stage-specific various clinical factors and serum MCP-1, TGF-beta1, and s-fractalkine levels were investigated. Furthermore, 57 patients with non-alcoholic CP were similarly evaluated in order to exclude influence of alcohol intake. RESULTS: Patients with CP showed significant higher levels of serum TGF-beta1 and s-fractalkine, but not MCP-1, compared to the controls. Serum TGF-beta1 in the severe stage and s-fractalkine in the mild and the severe stage of CP significantly increased compared to those of controls. However, it was observed that both TGF-beta1 and s-fractalkine levels were affected by alcohol intake. In patients with non-alcoholic CP, serum TGF-beta1 showed significant increase in the moderate stage of CP, and serum s-fractalkine revealed significant increase in the early stage of CP. CONCLUSION: It is suggested that the measurement of serum F-fractalkine is useful to diagnose early-stage CP. Moreover, the combined determination of both, s-fractalkine and TGF-beta1, in human sera may be helpful in evaluating the severity status of CP.
AIM: To clarify whether serum chemokine and cytokine levels can become useful biological and functional markers to assess the severity of chronic pancreatitis (CP). This study aimed at clarifying whether serum chemokine and cytokine levels can become useful biological and functional markers to assess the severity of CP. METHODS: Serum monocyte chemoattractant protein-1 (MCP-1), transforming growth factor beta-1 (TGF-beta1), and soluble type fractalkine (s-fractalkine) concentrations were examined in patients with CP (n = 109) and healthy controls (n = 116). Severity of disease was classified in patients with CP by a staging system. Relationships between stage-specific various clinical factors and serum MCP-1, TGF-beta1, and s-fractalkine levels were investigated. Furthermore, 57 patients with non-alcoholic CP were similarly evaluated in order to exclude influence of alcohol intake. RESULTS:Patients with CP showed significant higher levels of serum TGF-beta1 and s-fractalkine, but not MCP-1, compared to the controls. Serum TGF-beta1 in the severe stage and s-fractalkine in the mild and the severe stage of CP significantly increased compared to those of controls. However, it was observed that both TGF-beta1 and s-fractalkine levels were affected by alcohol intake. In patients with non-alcoholic CP, serum TGF-beta1 showed significant increase in the moderate stage of CP, and serum s-fractalkine revealed significant increase in the early stage of CP. CONCLUSION: It is suggested that the measurement of serum F-fractalkine is useful to diagnose early-stage CP. Moreover, the combined determination of both, s-fractalkine and TGF-beta1, in human sera may be helpful in evaluating the severity status of CP.
Authors: L Saurer; P Reber; T Schaffner; M W Büchler; C Buri; A Kappeler; A Walz; H Friess; C Mueller Journal: Gastroenterology Date: 2000-02 Impact factor: 22.682
Authors: Fanny Wai-Tsing Shek; Robert Christopher Benyon; Fiona Mairi Walker; Peter Raymond McCrudden; Sylvia Lin Foon Pender; Elizabeth Jean Williams; Penelope Ann Johnson; Colin David Johnson; Adrian Calvin Bateman; David Roger Fine; John Peter Iredale Journal: Am J Pathol Date: 2002-05 Impact factor: 4.307
Authors: Min Shi; Joshua Bradner; Aneeka M Hancock; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Un Jung Kang; Kevin C Cain; Yu Wang; Jan Aasly; David Goldstein; Jing Zhang Journal: Ann Neurol Date: 2011-03-11 Impact factor: 10.422
Authors: Hannah M Komar; Phil A Hart; Zobeida Cruz-Monserrate; Darwin L Conwell; Gregory B Lesinski Journal: Pancreas Date: 2017-09 Impact factor: 3.327
Authors: Eric J Jacobs; Christina C Newton; Debra T Silverman; Leticia M Nogueira; Demetrius Albanes; Satu Männistö; Michael Pollak; Rachael Z Stolzenberg-Solomon Journal: Cancer Causes Control Date: 2014-06-10 Impact factor: 2.506
Authors: Zobeida Cruz-Monserrate; Kristyn Gumpper; Valentina Pita; Phil A Hart; Christopher Forsmark; David C Whitcomb; Dhiraj Yadav; Richard T Waldron; Stephen Pandol; Hanno Steen; Vincent Anani; Natasha Kanwar; Santhi Swaroop Vege; Savi Appana; Liang Li; Jose Serrano; Jo Ann S Rinaudo; Mark Topazian; Darwin L Conwell Journal: Pancreatology Date: 2021-01-22 Impact factor: 3.996
Authors: Jami L Saloman; Gong Tang; Kimberly M Stello; Kristen E Hall; Xianling Wang; Samer AlKaade; Peter A Banks; Randall E Brand; Darwin L Conwell; Gregory A Coté; Christopher E Forsmark; Timothy B Gardner; Andres Gelrud; Michele D Lewis; Stuart Sherman; Adam Slivka; David C Whitcomb; Dhiraj Yadav Journal: Pancreatology Date: 2021-09-30 Impact factor: 3.996
Authors: Wenjun Zhu; Crystal Acosta; Brian MacNeil; Claudia Cortes; Howard Intrater; Yuewen Gong; Mike Namaka Journal: Biomed Res Int Date: 2013-09-24 Impact factor: 3.411